Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Palliative Care: Industry and Academia – Tensions and Opportunities

Dr Jim Cleary - IU Simon Cancer Center, Indianapolis, USA
Palliative Care: Industry and Academia – Tensions and Opportunities ( Dr Jim Cleary - IU Simon Cancer Center, Indianapolis, USA )
29 Apr 2021

Language and understanding: The complexity of insight in cancer care

Dr Tianna Martin - Beaumont Hospital, Dublin, Ireland
Language and understanding: The complexity of insight in cancer care ( Dr Tianna Martin - Beaumont Hospital, Dublin, Ireland )
22 Apr 2021

Decolonising palliative care

Dr Christian Ntizimira - African Center for Research on End of Life Care, Kigali, Rwanda
Decolonising palliative care ( Dr Christian Ntizimira - African Center for Research on End of Life Care, Kigali, Rwanda )
22 Apr 2021

Understanding patient experience in Europe: The first Global Lung Cancer Coalition Patient Experience Survey

Vanessa Beattie - Lung Cancer Nursing UK, Solihull, England
Understanding patient experience in Europe: The first Global Lung Cancer Coalition Patient Experience Survey ( Vanessa Beattie - Lung Cancer Nursing UK, Solihull, England )
22 Apr 2021

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC

Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK
CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC ( Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK )
19 Apr 2021

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world

Dr Martina Lorenzi - University of Padua, Padua, Italy
First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world ( Dr Martina Lorenzi - University of Padua, Padua, Italy )
16 Apr 2021

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma

Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany
Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma ( Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany )
16 Apr 2021

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma

Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )
16 Apr 2021

Healthy lifestyle may offset risk of lethal prostate cancer in men with high genetic risk

Dr Anna Plym - Harvard University, Boston, USA
Healthy lifestyle may offset risk of lethal prostate cancer in men with high genetic risk ( Dr Anna Plym - Harvard University, Boston, USA )
15 Apr 2021

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada
First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 ( Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada )
9 Apr 2021

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD  II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )
9 Apr 2021

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions

Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )
29 Mar 2021